Prevalence of pulmonary hypertension in hereditary spherocytosis

American Journal of Hematology

Volumn 86, Issue 12, 2011, Pages

  Crary, Shelley E ^a,b   Ramaciotti, Claudio ^a   Buchanan, George R ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Center for Cancer and Blood Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HEMOLYSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; HEREDITARY SPHEROCYTOSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RISK FACTOR; SICKLE CELL ANEMIA; SPLENECTOMY; THALASSEMIA;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; POSTOPERATIVE COMPLICATIONS; PREVALENCE; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; SPHEROCYTOSIS, HEREDITARY; SPLENECTOMY; TEXAS; TRICUSPID VALVE; YOUNG ADULT;

EID: 81355127498     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22182     Document Type: Article

References (30)

1. Crary SE, Buchanan GR. Vascular complications following splenectomy for hematologic disorders. Blood 2009; 114: 2861-2868.
2. Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8, 860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006; 96: 488-491.
3. Stewart GW, Amess JA, Eber SW, et al. Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol 1996; 93: 303-310.
4. Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost 2008; 6: 1289-1295.
5. Singer ST, Kuypers FA, Styles L, et al. Pulmonary hypertension in thalassemia: Association with platelet activation and hypercoagulable state. Am J Hematol 2006; 81: 670-675.
6. Phrommintikul A, Sukonthasarn A, Kanjanavanit R, et al. Splenectomy: A strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 2006; 92: 1467-1472.
7. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886-895.
8. Jais X, Ioos V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005; 60: 1031-1034.
9. Hoeper MM, Niedermeyer J, Hoffmeyer F, et al. Pulmonary hypertension after splenectomy? Ann Intern Med 1999; 130: 506-509.
10. Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93: 512-516.
11. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365: 44-53.
12. Gladwin MT, Kato GJ. Cardiopulmonary complications of sickle cell disease: Role of nitric oxide and hemolytic anemia. Hematology (Am Soc Hematol Educ Program) 2005: 51-57.
13. Jardine DL, Laing AD. Delayed pulmonary hypertension following splenectomy for congenital spherocytosis. Intern Med J 2004; 34: 214-216.
14. Smedema JP, Louw VJ. Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis. Cardiovasc J Afr 2007; 18: 84-89.
15. Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010; 116: 687-692.
16. Hebbel RP. Reconstructing sickle cell disease: A data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol 2011; 86: 123-154.
17. Cappellini MD, Grespi E, Cassinerio E, et al. Coagulation and splenectomy: An overview. Ann N Y Acad Sci 2005; 1054: 317-324.
18. Fontana V, Jy W, Ahn ER, et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res 2008; 122: 599-603.
19. Tang WH, Francis GS, Morrow DA, et al. National academy of clinicalbiochemistry laboratory medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007; 116: e99-e109.
20. Dentali F, Donadini M, Gianni M, et al. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med 2009; 4: 123-128.
21. Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97: 1230-1236.
22. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485-1494.
23. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 2004; 25: 2243-2278.
24. Crary SE, Troendle S, Ahmad N, et al. Traditional laboratory measures of cardiovascular risk in hereditary spherocytosis. Pediatric Blood Cancer 2010; 55: 684-689.
25. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.
26. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
27. Singer ST, Kuypers F, Fineman J, et al. The effect of thalassemia and other RBC hemolytic disorders and splenectomy on the frequency of pulmonary hypertension. ASH Annu Meeting Abstracts 2010; 116: 2077.
28. Hayag-Barin JE, Smith RE, Tucker FCJr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: A case report and review of the literature. Am J Hematol 1998; 57: 82-84.
29. Yock P, Popp R. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657-662.
30. Di Serio F, Ruggieri V, Varraso L, et al. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med 2005; 43: 1263-1273.